Sema4
GeneDx Q2 Revenues Increase 35 Percent, Boosted by Growth in Exome, Genome Tests
The genetic testing firm is using AI to improve genome interpretation and help customers raise low reimbursement rates for whole-exome testing.
GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement
The company executed a reverse stock split this month after its share price had languished below $1.00 since November.
GeneDx Q1 Revenues Fall 20 Percent but Beat Consensus Estimate
Molecular diagnostic testing volume grew across all continuing operations in Q1 as GeneDx completed the shutdown of underperforming Sema4 assets.
GeneDx to Execute 1-for-33 Reverse Stock Split
The genetic testing company, formerly known as Sema4, received a Nasdaq noncompliance notice in December as its stock has languished below $1.
GeneDx Q4 Revenues Grow 6 Percent but Miss Consensus Estimate
The firm reiterated an earlier forecast of $205 million to $220 million in revenues for 2023, representing a slight decline over 2022.
May 13, 2022
May 12, 2022
Sema4 Q1 Revenues Decline 16 Percent
Mar 15, 2022
Sema4 Q4 Revenues Decline 10 Percent
Jan 20, 2022
Jan 18, 2022
Sema4 to Acquire GeneDx for $623M
Jan 6, 2022
Nov 15, 2021
Sema4 Q3 Revenues Rise 12 Percent
Oct 8, 2021
BTIG Initiates Coverage of Sema4 With Buy Rating
Aug 16, 2021